bioaccess® vs Nicaragua

Nicaragua is a second-country option, not a first-in-human starting point. CONIS authorizes medicine trials under NTON 19001:2022 and Normativa-166 after ethics, scientific, and national-regulatory approvals. Section 13.1 requires a foreign product to hold authorization for research in humans from a recognized international regulator before a Nicaragua application, so plan it after an FDA IND or a first study elsewhere. Phase I is provided for, with healthy volunteers first and compassionate use by exception. There are no published device-specific trial rules, though ANRS lists a device clinical-investigation fee code (DDM-10). U.S. sanctions are list-based, so screening is required, and the State Department rates Nicaragua Level 3: Reconsider Travel. This site cites no bioaccess® entity, office, or completed study in Nicaragua.

Built for

Not the right fit if

Head-to-head: bioaccess® vs Nicaragua

Metricbioaccess®Nicaragua
Role in your planOne First-in-Human CRO that plans the first-in-human country and assesses Nicaragua as a second country for the protocolOne national pathway: CONIS authorization under NTON 19001:2022 and Normativa-166, after ethics, scientific, and ANRS approvals
Prior authorizationFirst-in-human country planned with U.S. regulatory anchoringA foreign product needs authorization for research in humans from a recognized international regulator before a Nicaragua application (NTON 19001:2022, section 13.1). Whether an FDA IND satisfies that condition is not confirmed in writing
Phase I requirementsConfirmed per protocol in the regulatory planHealthy volunteers first, compassionate use only by exception; a prior animal toxicity study including carcinogenicity and teratogenicity; an investigator's brochure; and a facility with infrastructure and staff adequate for Phase I (NTON 19001:2022, section 5.2.1; Normativa-166, Chapter VII)
Device investigationsRoute confirmed case by case with ANRS and CONISNo published device-specific trial rules. ANRS lists the authorization for the clinical investigation of medical devices at C$10,887.72, code DDM-10 (Circular ANRS-MLRG-0017-10-2024). Import for clinical research needs the CONIS authorization (Resolution 0009/2024)
Authority clockStudy-specific; confirmed per protocolNo total timeline published. The ANRS binding technical report is due within 45 business days when CONIS requests it (Normativa-166, Chapter XI). Not an ethics clock or a startup promise
Sanctions and travelCounterparty screening and travel planning built into the feasibility assessmentOFAC's program is list-based, not an embargo: only listed parties and entities they own 50 percent or more are blocked, so screening is required (31 CFR 582.201, 582.406). State Department advisory: Level 3, Reconsider Travel (13 May 2026)
Per-patient / program costBudget depends on study design; we provide a study-specific quote.There is no published Nicaragua cost or savings figure on this site; budget follows the protocol
Track record in the countryVerified programs are listed in the trial evidence registryThis site cites no bioaccess® entity, office, site, or completed study in Nicaragua

Comparison uses widely-known category facts about Nicaragua and published US benchmark ranges — not Nicaragua-specific figures. bioaccess® figures reflect our FIH-12™ operating model.

Sources

Why bioaccess® for first-in-human

Nicaragua is worth weighing after the first authorization, not before it. NTON 19001:2022 section 13.1 lets a foreign product apply only when it holds authorization for research in humans from a recognized international regulator. That makes Nicaragua a second country after an FDA IND or a first study elsewhere.

The medicine pathway is published. CONIS authorizes the trial after ethics, scientific, and national-regulatory approvals, and Phase I is provided for, with healthy volunteers first, compassionate use by exception, prior animal toxicity including carcinogenicity and teratogenicity, and a facility equipped for Phase I. Device investigations have an ANRS fee code (DDM-10) but no published device-specific rules, so the route is confirmed case by case.

bioaccess® is the same First-in-Human CRO on that file as on the others: Miami headquarters, U.S. regulatory anchoring, and a protocol-specific plan. We make capability and approach statements about Nicaragua, not claims of completed work, a local entity, or an office. Screening under OFAC's list-based program and planning around the State Department's Level 3 advisory are part of that plan.

Frequently asked questions

Is this the Nicaragua country page?

No. Our Nicaragua page, /clinical-trials-nicaragua, covers the CONIS pathway, the Phase I requirements, the dossier, insurance, and import in detail. This comparison weighs Nicaragua as a destination beside a bioaccess® plan.

Can Nicaragua be the first country for a first-in-human study?

Not for a foreign product. NTON 19001:2022 section 13.1 requires authorization for research in humans from a recognized international regulator before a Nicaragua application can be filed. Plan Nicaragua after an FDA IND or a first study elsewhere.

What does a Phase I file need?

Under NTON 19001:2022 section 5.2.1 and Normativa-166 Chapter VII: a reasoned ethics-committee report, informed consent, a protocol that defines a healthy individual or, by exception, specifies a compassionate-use situation, a detailed protocol, a prior animal toxicity study including carcinogenicity and teratogenicity, the investigator's brochure, and a facility adequate for Phase I.

Is there a device-trial pathway?

There are no published device-specific trial rules. ANRS lists the authorization for the clinical investigation of medical devices at C$10,887.72, code DDM-10 (Circular ANRS-MLRG-0017-10-2024), and Resolution 0009/2024 requires the CONIS authorization to import products for clinical research. The route is confirmed case by case with ANRS and CONIS.

Does bioaccess® run trials or have an office in Nicaragua?

This site does not say that. It cites no bioaccess® entity, office, site, or completed study in Nicaragua. Ask for a protocol-specific feasibility assessment.

Related reading

All CRO comparisons · First-in-Human CRO · Clinical Trials in Panama · Book a free 30-min strategy call